- Home
- SRRK
as 03-28-2025 4:00pm EST
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 3.3B | IPO Year: | 2018 |
| Target Price: | $40.43 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.76 - $46.98 | Next Earning Date: | 05-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 599.61% |
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moore Erin | SRRK | Interim PFO and PAO | Mar 24 '25 | Sell | $33.12 | 13,564 | $449,236.97 | 82,609 | |
| Peng Katie | SRRK | Director | Mar 17 '25 | Sell | $34.42 | 1,006 | $34,626.92 | 30,319 | |
| Myles Edward H | SRRK | COO & CFO | Mar 10 '25 | Sell | $35.35 | 142,292 | $5,068,974.19 | 140,740 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Feb 18 '25 | Sell | $37.33 | 72,645 | $2,714,767.40 | 131,286 | |
| Parlavecchio Caryn | SRRK | CHRO | Feb 18 '25 | Sell | $36.83 | 5,296 | $195,046.38 | 140,258 | |
| Backstrom Jay T. | SRRK | CHIEF EXECUTIVE OFFICER | Feb 18 '25 | Sell | $36.83 | 18,372 | $676,622.39 | 311,991 | |
| Ho Junlin | SRRK | GENERAL COUNSEL | Feb 18 '25 | Sell | $36.83 | 5,742 | $211,472.12 | 189,295 | |
| Myles Edward H | SRRK | COO & CFO | Feb 18 '25 | Sell | $36.83 | 7,809 | $287,597.66 | 140,740 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Jan 16 '25 | Sell | $44.20 | 7,347 | $324,716.83 | 131,286 | |
| Parlavecchio Caryn | SRRK | CHRO | Jan 16 '25 | Sell | $44.20 | 6,434 | $284,364.78 | 140,258 |
Latest Scholar Rock Holding Corporation News
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Scholar Rock Gets US FDA Priority Review for Potential Spinal Muscular Atrophy Treatment
Business Wire
5 days ago
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy
Clinical Trials Arena
13 days ago
Scholar Rock SMA drug shows muscle function benefit
MT Newswires
13 days ago
Scholar Rock Study of Potential Spinal Muscular Atrophy Treatment Meets Secondary Endpoints
Business Wire
13 days ago
Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Business Wire
15 days ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
17 days ago
Scholar Rock Holding Insider Sold Shares Worth $5,068,974, According to a Recent SEC Filing
Simply Wall St.
24 days ago
When Can We Expect A Profit From Scholar Rock Holding Corporation (NASDAQ:SRRK)?
Compare SRRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.